A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2+/HR+ Breast Cancer
Interventions: DRUG: ZW25 (Zanidatamab)|DRUG: Palbociclib|DRUG: Fulvestrant
Sponsor: Jazz Pharmaceuticals